Joseph "Audie" S. Black, PhD, ABN, is an Idaho native and board-certified clinical neuropsychologist. He is the founder of Idaho Neuropsychology, PLLC, where he provides comprehensive neuropsychological evaluations for adults with neurological injury and disease, with particular expertise in traumatic brain injury, neurodegenerative conditions, and complex neurocognitive and neuropsychiatric presentations. Dr. Black also provides short-term, targeted psychotherapy for individuals living with neurological conditions and caregiver support services. Prior to launching his private practice, Dr. Black practiced in both inpatient and outpatient hospital settings, including a Level-1 Trauma at Allegheny Health Network in Pittsburgh, PA and neurorehabilitation services at St. Luke’s Health System in Idaho. Dr. Black is a Diplomate of the American Board of Professional Neuropsychology and a former Associate Director of Training for the psychology internship at Allegheny General Hospital. He has actively contributed in professional education and services at the state and national levels.

Amy Brooks-Kayal, MD, FAES, FAAN, FANA, is Professor and Chair of the Department of Neurology and Andrew John Gabor MD, PhD Presidential Chair at UC Davis Health. Prior to that she was the Chief of Pediatric Neurology at University of Colorado School of Medicine and Children's Hospital Colorado. She has been a clinical pediatric epileptologist for 30 years, and have been an NIH-funded physician-scientist who studies epilepsy for the same period. The focus of her research program is to define the cellular and molecular pathways that mediate the development of epilepsy following brain injury, and how they contribute to later development of epilepsy (epileptogenesis), with the goal of identification of novel therapeutic approaches to the prevention and treatment of both the seizures and cognitive co-morbidities associated with epilepsy. She has been very active in the Epilepsy and Neuroscience communities, previously serving as President of the American Epilepsy Society (AES), as a member of the NINDS Advisory Council, and on the Scientific Program Committees of AAN, AES and Society for Neuroscience. She has received the AES Founders Award, the Child Neurology Society Bernard Sachs Award and the ILAE Ambassador for Epilepsy Award for my lifetime contributions to epilepsy research and clinical care.

David E. Burdette, MD, is section chief of epilepsy and clinical neurophysiology at Corewell Health System in Grand Rapids, Michigan. He is also an assistant professor at Michigan State University College of Human Medicine in Grand Rapids, Michigan.

Dr. Burdette earned his medical degree from Boston University and completed neurology residency at Boston University, as well. He completed fellowships in epilepsy and clinical neurophysiology at the University of Michigan Medical Center in Ann Arbor, Michigan.

Dr. Burdette is principal investigator on several ongoing clinical trials of novel pharmaceutical and surgical treatments of medically intractable epilepsy. He has published numerous manuscripts on the pharmacologic and neuromodulatory treatments of refractory epilepsy and has authored textbook chapters on topics including epilepsy, antiseizure medications, advances in electroencephalography, and responsive neurostimulation. His primary research interest is neuromodulation, particularly responsive neurostimulation of thalamic nuclei.

Fuki Marie Hisama, MD, is Division Chief of Medical Genetics and Genomics at University of California Irvine. She is dual board certified in Neurology and Clinical Genetics. She received her M.D. from the University of Chicago, and her graduate medical education and research training at Yale New Haven Hospital. She has been a faculty member at Yale University, Boston Children's Hospital, the University of Washington before moving to UCI Irvine in 2025. Dr. Hisama has broad expertise in clinical genetics, as well as pediatric and adult neurogenetics. She co-chaired the first evidence-based practice guideline (in 2021) on clinical use of exome and genome sequencing. She is nationally recognized as a thought leader in Clinical and Neurogenetics practice and education, and has served with the Accreditation Council of Graduate Medical Education, the American Board of Medical Genetics and Genomics, American Academy of Neurology, American College of Medical Genetics, American Society of Human Genetics and the NIH Medical Scientist Partnership Program.

W. Curt LaFrance, Jr, MD, MPH, FAAN, FAPNA, FAES, DLFAPA, is a professor of psychiatry and neurology at Brown University Medical School and runs the neuropsychiatry and behavioral neurology clinic at Rhode Island Hospital. He is Director of the VA Mind Brain Program, Program Director for VA NEXCSS Tele-Neuropsychiatry Clinic. He trained in Brown's combined neurology/psychiatry residency and is double boarded. He is the ILAE Neuropsychiatry Commission Chair and has chaired ILAE and American Epilepsy Society NES Task Forces. He has received grants from EF, AES, Foundations, VA, DoD, and a NINDS K23 Award. He trains clinicians nationally using distance supervision in neurobehavioral therapy (NBT). His research focuses on developing new biomarkers and treatments for neuropsychiatric disorders. A goal of his work at Brown, nationally and internationally, has been to bridge neurology and psychiatry clinical practice and scientific research and to dissolve arbitrary boundaries between the two fields. 

Edward “Rusty” Novotny M.D., FAAN, FAES, FACNS, is Professor of Neurology and Pediatrics at the University of Washington School of Medicine and the Director of the Epilepsy Program at Seattle Children's Hospital. He has adjunct appointments in Neurosurgery and Radiology and serves as a principal investigator in the Center of Integrative Brain Research at the Seattle Children’s Research Institute. His clinical residency and fellowship training was in: child neurology clinical neurophysiology, and epilepsy at Stanford and Yale. His clinical and basic science postdoctoral training was in advanced neuroimaging at Yale University with support from NIH training grants and fellowships. As a resident, he was the recipient of the S. Weir Mitchell award from the American Academy of Neurology for investigation of a family with a novel mitochondrial disorder. After moving to Seattle Children's Hospital, he became site PI for the NIH funded Epilepsy Phenome/Genome Project. As Director of the epilepsy program, he has led development of multimodal imaging and advanced signal processing of neurophysiological data as an interdisciplinary program with involvement of investigators from engineering, computer science, genetics and physics with our clinical neuroscience center. This program focuses on investigations of somatic mosaicism of focal cortical dysplasias and malformations of cortical development to develop targeted surgical and medical treatments.

neuropsychologist with subspecialty certification in pediatric neuropsychology. She is the director of neuropsychology and the neuropsychology director of epilepsy at Seattle Children's Hospital and an associate professor of neurology at University of Washington School of Medicine. Dr. Patrick completed her PhD in clinical psychology at Drexel University with a major area of study in neuropsychology and then completed an APA accredited internship and 2-year neuropsychology fellowship at Nationwide Children's Hospital. Clinically, she sees a wide range of neurology patients with specialization in epilepsy and epilepsy surgery. Her research focuses on clinical applications of pediatric epilepsy such as use of fMRI, multi-disciplinary care models, and factors related to epilepsy surgery outcomes. Dr. Patrick is the co-chair of the Neuropsychology Special Interest Group for the Pediatric Epilepsy Research Consortium and serves on the professional advisory board of the Epilepsy Foundation of Washington and on the editorial board of Epilepsy and Behavior. She has a book in progress on neuropsychological profiles in pediatric epilepsy which will be published by Oxford Press this year.

University of Washington and director of the UW Regional Epilepsy Center, a high volume NAEC level 4 center serving Washington State and surrounding states in the Pacific Northwest and Intermountain West. In addition to his clinical work treating patients with medical refractory epilepsy and performing evaluations for epilepsy surgery, he is a clinician scientist with 26 years of NIH funding. His reseearch focuses on molecular mechanisms of epilepsy and on the comparative efficacy of antiseizure medications in patients with refractory epilepsy.

John M. Stern, MD, MA, FAES, FANA, FAAN, is Professor and Director of the Epilepsy Clinical Program in the Department of Neurology at the Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is also Director of UCLA’s Epilepsy Fellowship Training Program and Medical Director of UCLA’s Seizure Disorder Center.

Focused on seizures, epilepsy, and clinical neurophysiology, Dr. Stern maintains an active clinical practice that includes outpatient and inpatient care for seizures and epilepsy. He also has extensive experience as an investigator in clinical research studies and clinical trials related to epilepsy diagnosis and treatment. His 360 publications include 6 books and 200 peer-reviewed research papers, chapters, and reviews. Among the publications, one was awarded best clinical research publication of the year by Epilepsia Open and another was recognized as among the best of the year by Epilepsia.